Združene države Amerike - angleščina - NLM (National Library of Medicine)

wilshire pharmaceuticals - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u), fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - ciprofloxacin and fluocinolone acetonide otic solution is indicated for the treatment of acute otitis media with tympanostomy tubes (aomt) in pediatric patients (aged 6 months and older) due to staphylococcus aureus , streptococcus pneumoniae , haemophilus influenzae , moraxella catarrhalis , and pseudomonas aeruginosa . ciprofloxacin and fluocinolone acetonide otic solution is contraindicated in: - patients with known hypersensitivity to fluocinolone acetonide or other corticosteroids, ciprofloxacin or other quinolones, or to any other components of ciprofloxacin and fluocinolone acetonide otic solution. - viral infections of the external ear canal, including varicella and herpes simplex infections and fungal otic infections. risk summary ciprofloxacin and fluocinolone acetonide otic solution is negligibly absorbed following otic administration and maternal use is not expected to result in fetal exposure to ciprofloxacin and fluocinolone acetonide [see clinical pharmacology (12.3)]. risk summary ciprofloxaci

Združene države Amerike - angleščina - NLM (National Library of Medicine)

xspire pharma, llc - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u), fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - ciprofloxacin and fluocinolone acetonide otic solution is indicated for the treatment of acute otitis media with tympanostomy tubes (aomt) in pediatric patients (aged 6 months and older) due to staphylococcus aureus , streptococcus pneumoniae , haemophilus influenzae , moraxella catarrhalis , and pseudomonas aeruginosa . ciprofloxacin and fluocinolone acetonide otic solution is contraindicated in: - patients with known hypersensitivity to fluocinolone acetonide or other corticosteroids, ciprofloxacin or other quinolones, or to any other components of ciprofloxacin and fluocinolone acetonide otic solution. - viral infections of the external ear canal, including varicella and herpes simplex infections and fungal otic infections. risk summary ciprofloxacin and fluocinolone acetonide otic solution is negligibly absorbed following otic administration and maternal use is not expected to result in fetal exposure to ciprofloxacin and fluocinolone acetonide [see clinical pharmacology (12.3)]. risk summary ciprofloxacin and fluocinolone acetonide otic solution is negligibly absorbed by the mother following otic administration and breastfeeding is not expected to result in exposure of the infant to ciprofloxacin and fluocinolone acetonide [ see clinical pharmacology (12.3) ]. ciprofloxacin and fluocinolone acetonide otic solution has been studied in patients as young as 6 months in adequate and well-controlled clinical trials. no major differences in safety and effectiveness have been observed between adult and pediatric patients [ see indications and usage (1)and dosage and administration (2)]. clinical studies of ciprofloxacin and fluocinolone acetonide otic solution did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. read this instructions for use that comes with ciprofloxacin and fluocinolone acetonide otic solution before you start using it and each time you get a refill. there may be new information. this information does not take the place of talking with your healthcare provider about your medical condition or treatment. important information about ciprofloxacin and fluocinolone acetonide otic solution : - ciprofloxacin and fluocinolone acetonide otic solution is for use in the ear only (otic use) . do not inject ciprofloxacin and fluocinolone acetonide otic solution or use ciprofloxacin and fluocinolone acetonide otic solution in the eye. - use ciprofloxacin and fluocinolone acetonide otic solution exactly as your healthcare provider tells you to use it. how should i use ciprofloxacin and fluocinolone acetonide otic solution? this instructions for use has been approved by the food and drug administration.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

arbor pharmaceuticals - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u), fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - ciprofloxacin 872.5 ug in 0.25 ml - otovel is indicated for the treatment of acute otitis media with tympanostomy tubes (aomt) in pediatric patients (aged 6 months and older) due to staphylococcus aureus, streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, and pseudomonas aeruginosa . otovel is contraindicated in: - patients with known hypersensitivity to fluocinolone acetonide or other corticosteroids, ciprofloxacin or other quinolones, or to any other components of otovel. - viral infections of the external ear canal, including varicella and herpes simplex infections and fungal otic infections. risk summary otovel is negligibly absorbed following otic administration and maternal use is not expected to result in fetal exposure to ciprofloxacin and fluocinolone acetonide [see clinical pharmacology (12.3) ]. risk summary otovel is negligibly absorbed by the mother following otic administration and breastfeeding is not expected to result in exposure of the infant to ciprofloxacin and fluocinolone acetonide [see clinical phar

Izrael - angleščina - Ministry of Health

cts ltd - ciprofloxacin as hydrochloride; fluocinolone acetonide - ear drops - ciprofloxacin as hydrochloride 3 mg / 1 ml; fluocinolone acetonide 0.25 mg / 1 ml - ciprofloxacin - ciprofloxacin - cetraxal is indicated in adults and in children aged 6 months and older for the following infections:- acute otitis externa (aoe)- acute otitis media in patients with tympanostomy tubes (aomt)caused by ciprofloxacin susceptible microorganisms.consideration should be given to official guidance on the appropriate use of antibacterial agents.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

physicians total care, inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.11 mg in 118.28 ml - fluocinolone acetonide 0.01% topical oil is indicated for the topical treatment of atopic dermatitis in adult patients. fluocinolone acetonide 0.01% topical oil is indicated for the topical treatment of moderate to severe atopic dermatitis in pediatric patients, 3 months and older for up to 4 weeks. safety and effectiveness in pediatric patients younger than 3 months of age have not been established. apply the least amount of fluocinolone acetonide 0.01% topical oil needed to cover the affected areas. as with other corticosteroids, fluocinolone acetonide 0.01% topical oil should be discontinued when control of disease is achieved. contact the physician if no improvement is seen within 2 weeks. fluocinolone acetonide 0.01% topical oil should not be applied to the diaper area; diapers or plastic pants may constitute occlusive use. fluocinolone acetonide 0.01% topical oil should not be used on the face, axillae, or groin unless directed by the physician.  application to intertriginous areas should be avoided due

Združene države Amerike - angleščina - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.11 mg in 1 ml - fluocinolone acetonide topical oil, 0.01% is indicated for the topical treatment of atopic dermatitis in adult patients. fluocinolone acetonide topical oil, 0.01% is indicated for the topical treatment of moderate to severe atopic dermatitis in pediatric patients, 3 months and older for up to 4 weeks. safety and effectiveness in pediatric patients younger than 3 months of age have not been established. apply the least amount of fluocinolone acetonide topical oil, 0.01% needed to cover the affected areas. as with other corticosteroids, fluocinolone acetonide topical oil, 0.01% should be discontinued when control of disease is achieved. contact the physician if no improvement is seen within 2 weeks. fluocinolone acetonide topical oil, 0.01% should not be applied to the diaper area; diapers or plastic pants may constitute occlusive use. fluocinolone acetonide topical oil, 0.01% should not be used on the face, axillae, or groin unless directed by the physician. application to intertriginous areas should be avo

Združene države Amerike - angleščina - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.11 mg in 118.28 ml - fluocinolone acetonide topical oil is indicated for the topical treatment of atopic dermatitis in adult patients. fluocinolone acetonide topical oil is indicated for the topical treatment of moderate to severe atopic dermatitis in pediatric patients, 3 months and older for up to 4 weeks. safety and effectiveness in pediatric patients younger than 3 months of age have not been established. apply the least amount of fluocinolone acetonide topical oil needed to cover the affected areas. as with other corticosteroids, fluocinolone acetonide topical oil should be discontinued when control of disease is achieved. contact the physician if no improvement is seen within 2 weeks. fluocinolone acetonide topical oil should not be applied to the diaper area; diapers or plastic pants may constitute occlusive use. fluocinolone acetonide topical oil should not be used on the face, axillae, or groin unless directed by the physician. application to intertriginous areas should be avoided due to the increased risk of local adver

Združene države Amerike - angleščina - NLM (National Library of Medicine)

amneal pharmaceuticals llc - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.11 mg in 118.28 ml - fluocinolone acetonide 0.01% topical oil is a low to medium potency corticosteroid indicated: in adult patients for the treatment of psoriasis of the scalp (scalp oil). fluocinolone acetonide 0.01% topical oil is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. this product contains refined peanut oil nf (see precautions section).

Združene države Amerike - angleščina - NLM (National Library of Medicine)

avkare, inc. - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.11 mg in 118.28 ml - fluocinolone acetonide 0.01% topical oil is a low to medium potency corticosteroid indicated: in adult patients for the treatment of psoriasis of the scalp (scalp oil). fluocinolone acetonide 0.01% topical oil is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. this product contains refined peanut oil nf (see precautions section).

Združene države Amerike - angleščina - NLM (National Library of Medicine)

seton pharmaceuticals - fluocinolone acetonide (unii: 0cd5fd6s2m) (fluocinolone acetonide - unii:0cd5fd6s2m) - fluocinolone acetonide 0.11 mg in 1 ml - fluocinolone acetonide 0.01% topical oil (body oil) is indicated for the topical treatment of atopic dermatitis in adult patients. fluocinolone acetonide 0.01% topical oil (body oil) is indicated for the topical treatment of moderate to severe atopic dermatitis in pediatric patients, 3 months and older for up to 4 weeks. safety and effectiveness in pediatric patients younger than 3 months of age have not been established. apply the least amount of fluocinolone acetonide 0.01% topical oil needed to cover the affected areas. as with other corticosteroids, fluocinolone acetonide 0.01% topical oil should be discontinued when control of disease is achieved. contact the physician if no improvement is seen within 2 weeks. fluocinolone acetonide 0.01% topical oil should not be applied to the diaper area; diapers or plastic pants may constitute occlusive use. fluocinolone acetonide 0.01% topical oil should not be used on the face, axillae, or groin unless directed by the physician. application to intertriginous areas